Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
September 25, 2024 07:08 ET
|
Oruka Therapeutics, Inc.
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding...
Oruka Therapeutics Announces $200 Million Private Placement
September 12, 2024 07:05 ET
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new...
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
September 12, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
September 03, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to...
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
June 26, 2024 08:00 ET
|
Oruka Therapeutics, Inc.
Paul Quinlan joins as General Counsel Alan Lada joins as VP of Investor Relations Kristine Ball, President & CEO of Antiva Biosciences, appointed to Board of Directors MENLO...
Oruka Therapeutics to Present at the 2024 Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET
|
Oruka Therapeutics, Inc.
WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic...
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn and Rajiv Panwar
May 22, 2024 08:00 ET
|
Oruka Therapeutics, Inc.
Joe Senn, PhD, joins as SVP of Nonclinical Research & Development Rajiv Panwar, PhD, joins as VP and Head of Chemistry, Manufacturing, and Controls Appointments strengthen Oruka’s executive...
Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer
April 24, 2024 08:00 ET
|
Oruka Therapeutics, Inc.
Dr. Goncalves, former CMO at Cara Therapeutics, joins Oruka as CMO Eugenia Levi, PharmD, former Head of Global Medical Affairs for Cosentyx at Novartis, also joins as VP, Medical Affairs ...
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
April 03, 2024 07:30 ET
|
Oruka Therapeutics, Inc.
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded...